Entos Pharmaceuticals Inc.
$130,700.00 CAD
≈ 20 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- August 1, 2025 – March 31, 2027
- Reference
- nrc-cnrc:172-2025-2026-Q2-1034236
Published purpose
As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimized for delivery of DNA-based genetic medicines to target cell types of the retina to address unmet medical need in rare ophthalmological diseases, including Stargardt Disease. The project will evaluate novel DNA based genetic medicines, encapsulated with Entos’ Fusogenix PLV formulations, for enhanced bioactivity, durable transgene expression and optimal tolerability in small animal models.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions